.png?width=2000&name=Webbanner_Devyser_PR-GBT_2506%20(1).png)
Devyser announces study publication demonstrating dd-cfDNA detection in dual donor kidney transplant patients
Devyser Diagnostics AB announces today an article titled “Detection of donor-derived cell-free DNA...
Event I May 24-25, 2023
5th International Meeting of Cell-Free DNA
We are excited to announce that we will be attending the cfDNA2023 conference. The meeting promises to provide an excellent overview of the field as presented by key experts and give us the opportunity to discuss scientific and clinical topics with peers from the field. We look forward to learning from and contributing to the conversation at cfDNA2023.
Take a look at our whitepaper
Dr. Agneta Wikman, Associate Professor at Karolinska University Hospital explores an approach that uses non-invasive prenatal testing to determine the fetal RHD status, allowing targeted administration of antenatal anti-D prophylaxis only to those who will benefit from it. Learn more about the current strategies of fetal RHD and the experiences and considerations surrounding planning a fetal RHD screening program.
Listen to the audio & e-book
Choosing and implementing the best screening method for non-invasive fetal-RHD testing. Learn from clinical experts about the shift in today’s screening method for non-invasive fetal-RHD testing. Dr Wikman is a professor and specialist in Transfusion Medicine and Laboratory Medicine.
News | June 26, 2025
Devyser launches Devyser HLA Loss: A high-precision NGS assay for post-transplant researchNews | October 29, 2024
Devyser seeks to secure FDA approval for NGS test for kidney transplant monitoringNews | October 28, 2024
Devyser Compact achieves Class III approval in China
Devyser Accept cfDNA demonstrates high performance in newly published peer-reviewed article
Devyser’s NGS products for monitoring of kidney and stem cell transplant patients receive IVDR approvals
Devyser’s novel test for detecting donor-derived cell-free DNA in blood samples from...
Early detection of relapse and early therapeutic intervention: The benefits of Devyser NGS method for chimerism analysis
A better patient care is the final objective for Dr. Helena Devos and the team at Sint Jan’s...